SMARCA4型
瑞士/瑞士法郎
合成致死
染色质重塑
癌症研究
RNA干扰
基因沉默
癌症
染色质
生物
基因
遗传学
核糖核酸
突变体
作者
Takahiro Oike,Hideaki Ogiwara,Yuichi Tominaga,Kentaro Ito,Osamu Ando,Koji Tsuta,Tatsuji Mizukami,Yoko Shimada,Hisanori Isomura,Mayumi Komachi,Koh Furuta,Shun-ichi I. WATANABE,Takashi Nakano,Jun Yokota,Takashi Kohno
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2013-07-19
卷期号:73 (17): 5508-5518
被引量:306
标识
DOI:10.1158/0008-5472.can-12-4593
摘要
The occurrence of inactivating mutations in SWI/SNF chromatin-remodeling genes in common cancers has attracted a great deal of interest. However, mechanistic strategies to target tumor cells carrying such mutations are yet to be developed. This study proposes a synthetic-lethality therapy for treating cancers deficient in the SWI/SNF catalytic (ATPase) subunit, BRG1/SMARCA4. The strategy relies upon inhibition of BRM/SMARCA2, another catalytic SWI/SNF subunit with a BRG1-related activity. Immunohistochemical analysis of a cohort of non-small-cell lung carcinomas (NSCLC) indicated that 15.5% (16 of 103) of the cohort, corresponding to preferentially undifferentiated tumors, was deficient in BRG1 expression. All BRG1-deficient cases were negative for alterations in known therapeutic target genes, for example, EGFR and DDR2 gene mutations, ALK gene fusions, or FGFR1 gene amplifications. RNA interference (RNAi)-mediated silencing of BRM suppressed the growth of BRG1-deficient cancer cells relative to BRG1-proficient cancer cells, inducing senescence via activation of p21/CDKN1A. This growth suppression was reversed by transduction of wild-type but not ATPase-deficient BRG1. In support of these in vitro results, a conditional RNAi study conducted in vivo revealed that BRM depletion suppressed the growth of BRG1-deficient tumor xenografts. Our results offer a rationale to develop BRM-ATPase inhibitors as a strategy to treat BRG1/SMARCA4-deficient cancers, including NSCLCs that lack mutations in presently known therapeutic target genes.
科研通智能强力驱动
Strongly Powered by AbleSci AI